Table 2 Clinical characteristics with regard to the presence of Candida in the bile fluid

Patients

120

30

15

15

Age at diagnosis (years)

32.0 ± 1.1*

31.0 ± 2.3

37.0 ± 3.6

27.0 ± 2.9

Male sex

87 (72.5)

21 (70.0)

9 (60.0)

12 (80.0)

IBD

86 (71.7)

22 (73.3)

10 (66.7)

12 (80.0)

Overlap with autoimmune hepatitis

11 (9.2)

2 (6.7)

2 (13.3)

0 (0.0)

Dominant stenosis

76 (63.3)

24 (80.0)

11 (86.7)

13 (73.3)

- at first diagnosis

17 (14.2)

5 (16.7)

2 (13.3)

3 (20.0)

- time from first diagnosis, years

5.9 ± 5.7

5.6 ± 4.5

5.6 ± 4.9

5.6 ± 4.4

Number of ERCs per patient

3.0 ± 0.3

4.0 ± 0.6

4.0 ± 0.7

4.0 ± 1.0

Bilirubin (mg/dL)

0.9 ± 0.3

0.9 ± 0.9

1.0 ± 0.7

0.8 ± 1.6

-1.1

ALT (IU/L)

88.7 ± 10.5

118.0 ± 23.2

104.6 ± 45.6

124 ± 12.8

-23

AST (IU/L)

53.9 ± 6.2

82.0 ± 18.3

90.4 ± 24.4

70.0 ± 28.1

-19

AP (IU/L)

240.4 ± 23.0

266.5 ± 41.6

270.0 ± 80.0

265.0 ± 24.3

-175

GGT (IU/L)

247.5 ± 31.1

344.5 ± 67.7^a

448.0 ± 112.9^a

279 ± 62.6

-60

Albumin (g/dL)

41.0 ± 0.6

45.0 ± 1.5

41.0 ± 2.7

45.0 ± 1.3^a

35-55

Mayo Risk Score

-0.25 ± 0.1

-0.28 ± 0.3

0.04 ± 0.3

-0.3 ± 0.4

Development of CCA

6 (5.0)

5 (16.7)^a

4 (26.7)^a

1 (6.7)

Death

8 (6.7)

4 (13.3)

3 (20.0)

1 (6.7)

OLT

20 (16.8)

14 (46.7)^a

5 (33.3)

9 (60.0)^a

Death/OLT

28 (23.3)

18 (60.0)^a

8 (53.3)

10 (66.7)^a

Survival free of liver transplantation (years)

20.1 ± 2.1

11.5 ± 2.6^a

17.8 ± 7.3

11.1 ± 2.1^a